These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15485310)

  • 1. Darbepoetin alfa for the treatment of cancer-related anemia: an update.
    Pirker R
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):735-44. PubMed ID: 15485310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darbepoetin alfa: potential role in managing anemia in cancer patients.
    Pirker R; Smith R
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J
    Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J
    Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
    Stevenson JG; Natale JJ
    Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia in cancer patients: significance, epidemiology, and current therapy.
    Tchekmedyian NS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
    Henry DH
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals.
    Vansteenkiste J; Wauters I
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1347-55. PubMed ID: 17944560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
    Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF
    Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Rossi G; Foote M
    Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
    Glaspy JA
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):71-7. PubMed ID: 12380957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approaches to anemia associated with cancer and chemotherapy.
    Kolesar JM
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.